Global Rapid Acting Insulin Market Report Forecast by Product (Lispro Insulin, Aspart Insulin, Glulisine Insulin) Indication (Type 1 Diabetes, Type 2 Diabetes) Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Stores), Countries and Company Analysis (2024-2032)
Buy NowRapid Acting Insulin Market Analysis
The Global Rapid Acting Insulin Market will reach US$ 11.17 billion by 2032, up from US$ 7.36 billion in 2023, with a CAGR of 4.75 % between 2024 and 2032. Some of the key drivers driving the market include the rising risks of severity and mortality among patients, the general public's growing interest in customized medicine, and the rising costs associated with research and development (R&D) activities.
Rapid Acting Insulin Industry Overview
One kind of insulin used to treat diabetes is rapid-acting insulin, which is particularly useful for controlling blood sugar rises that occur after meals. It acts within 15 minutes of injection and is intended to resemble the body's normal insulin response following meals. This quick action works to manage the body's glucose metabolism, which in turn helps to properly control blood sugar levels. Fast-acting insulin can effectively lower elevated blood sugar levels during this crucial window of time since it peaks in action one to two hours after injection. It enables diabetics to schedule their injections in accordance with food intake, offering a more individualized course of care. It improves the way diabetes is managed, giving patients a higher quality of life and lowering their risk of consequences from high blood sugar.
| Report Features | Details |
|
Base Year |
2023 |
|
Forecast Years |
2024 - 2032 |
|
Historical Years |
2019 - 2023 |
|
Market Size in 2023 |
US$ 7.36 Billion |
|
Market Forecast in 2032 |
US$ 11.17 Billion |
|
Market Growth Rate (2024-2032) |
4.74% |
Growth drivers of Rapid Acting Insulin Market
Constant Progress in Technology
Insulin administration systems have been completely transformed by advances in medical technology, making them more accurate and user-friendly. Patients with diabetes are increasingly using insulin pens, insulin pumps, and continuous glucose monitoring (CGM) devices, which make administering insulin easier and more accurate. The need for rapid-acting insulin formulations is increased by the fact that they are made to function best with these contemporary delivery methods. While insulin pumps supply an ongoing, customized insulin infusion based on each patient's needs, insulin pens offer a discrete and practical method of delivering the drug. The quality of life for patients has been improved overall, glycemic control has improved, and the danger of hypoglycemia episodes has decreased thanks to these technological advancements. Consequently, rapid-acting insulin's compatibility with these cutting-edge gadgets has emerged as a key factor propelling the market's expansion.
Raising Knowledge and Improving the Infrastructure of Healthcare
The need for fast-acting insulin has been further exacerbated by rising healthcare costs and increased knowledge about diabetes and its management. The number of people seeking proper treatment has increased as a result of diabetes awareness campaigns, educational activities, and screening programs that have led to early diagnosis and prompt patient intervention. Rapid-acting insulin is being prescribed by doctors and other medical professionals more frequently to help patients improve their postprandial glucose management and avoid hyperglycemic episodes and long-term consequences. Governments and healthcare institutions are also funding diabetes management initiatives, which enhances accessibility to necessary drugs like fast-acting insulin. The rise of the rapid-acting insulin market is facilitated by improved healthcare facilities, increasing affordability of diabetes treatment, and more awareness of the disease.
North America Rapid Acting Insulin Market
Diabetes is highly prevalent in North America, where occurrences of the disease have been alarmingly rising in both the US and Canada over time. The area boasts a firmly established healthcare system with a focus on diabetes care and management. Advanced medical technology, insulin administration tools, and continuous glucose monitoring systems have become widely available, improving patient care and facilitating the broad use of insulin therapy with quick onset of action. Furthermore, the pharmaceutical industry's research and development is mostly concentrated on North America, which has resulted in the launch of novel and potent formulations of fast-acting insulin. This ongoing emphasis on improvements guarantees that the area will continue to play a significant role in determining how diabetes is treated in the future. Furthermore, a sizable section of the population in North America has simpler access to diabetic treatments, such as rapid-acting insulin, because to the country's robust healthcare regulations and insurance coverage. The region's strong market share can be attributed in large part to its accessibility.
Rapid Acting Insulin Company Analysis
Adocia, Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals Co. Ltd., Geropharm, MannKind Corporation, Merck & Co. Inc., Novo Nordisk A/S, Sanofi S.A., Wockhardt Ltd. are the leading companies in the Rapid Acting Insulin market.
Rapid Acting Insulin Company News
November 2022 - The Global Biosimilars Business of Viatris has been fully acquired by Biocon Limited. Biocon Biologics is now closer to patients, clients, and payors thanks to the acquisition, which gives it direct commercial capabilities and supporting infrastructure in various emerging regions as well as advanced markets.
May 2022 - The acquisition of Zealand Pharma's V-Go® Insulin Delivery Device has been announced by MannKind Corporation. Through the purchase of V-Go, MannKind is able to broaden its offering and reaffirm its dedication to offering cutting-edge mealtime diabetes treatments.
Product – Market breakup in 3 viewpoints:
- Lispro Insulin
- Aspart Insulin
- Glulisine Insulin
Indication – Market breakup in 2 viewpoints:
- Type 1 Diabetes
- Type 2 Diabetes
Distribution Channel – Market breakup in 3 viewpoints:
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Stores
Countries – Market breakup in 25 viewpoints:
North America
- United States
- Canada
Europe
- France
- Germany
- Italy
- Spain
- United Kingdom
- Belgium
- Netherland
- Turkey
Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
- Malaysia
- Indonesia
- Australia
- New Zealand
Latin America
- Brazil
- Mexico
- Argentina
Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
All the key players have been covered from 5 Viewpoints:
- Overview
- Key Persons
- Product Portfolio
- Recent Development & Strategies
- Revenue Analysis
Key Players Analysis:
- Adocia
- Biocon Limited
- Eli Lilly and Company
- Gan & Lee Pharmaceuticals Co. Ltd.
- Geropharm
- MannKind Corporation
- Merck & Co. Inc.
- Novo Nordisk A/S
- Sanofi S.A.
- Wockhardt Ltd.
Report Details:
| Report Features | Details |
| Base Year |
2023 |
| Historical Period |
2019 - 2023 |
| Forecast Period |
2024 - 2032 |
| Market |
US$ Billion |
| Segment Covered |
Product, Indication, Distribution Channel and Countries |
| Countries Covered |
|
| Companies Covered |
|
| Customization Scope |
20% Free Customization |
| Post-Sale Analyst Support |
1 Year (52 Weeks) |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
Key Questions Answered in This Report:
- How big is the Rapid Acting Insulin industry?
- What is the Rapid Acting Insulin industry growth rate?
- Who are the key players in Rapid Acting Insulin industry?
- What are the factors driving the Rapid Acting Insulin industry?
- Which Region held the largest market share in the Rapid Acting Insulin industry?
- What segments are covered in the Rapid Acting Insulin Market report?
Customization Services available
- Analysis of Market Size and Its Segments
- More Company Profiles (Upto 10 without any additional cost):
- Additional Countries (Other than mentioned Countries):
- Region/Country Specific Reports:
- Market Entry Strategy:
- Region-Specific Market Dynamics:
- Regional Market Share Analysis:
- Trade Analysis:
- Production Insights:
- Others Customized Requests:
For more information contact our analysts.
Need More Assistance?
- Talk to our analysts to get more precious information on the current market trends.
- Include more countries and segments and customize the report based on the final requirement.
- Get a competitive advantage in your industry by knowing the report findings and making a positive impact on your revenues and operations.
- Our analysts are always ready to provide more help and pertinent information if you need any additional assistance.
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
4.3 Opportunities
5. Global Rapid Acting Insulin Market
6. Market Share Analysis
6.1 By Product
6.2 By Indication
6.3 By Distribution Channel
6.4 By Countries
7. Product
7.1 Lispro Insulin
7.2 Aspart Insulin
7.3 Glulisine Insulin
8. Indication
8.1 Type 1 Diabetes
8.2 Type 2 Diabetes
9. Distribution Channel
9.1 Hospital Pharmacies
9.2 Drug Stores and Retail Pharmacies
9.3 Online Stores
10. Countries
10.1 North America
10.1.1 United States
10.1.2 Canada
10.2 Europe
10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium
10.2.7 Netherland
10.2.8 Turkey
10.3 Asia Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 Australia
10.3.5 South Korea
10.3.6 Thailand
10.3.7 Malaysia
10.3.8 Indonesia
10.3.9 New Zealand
10.4 Latin America
10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina
10.5 Middle East & Africa
10.5.1 South Africa
10.5.2 Saudi Arabia
10.5.3 UAE
11. Porter’s Five Forces Analysis
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes
12. SWOT Analysis
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat
13. Key Players Analysis
13.1 Adocia
13.1.1 Overview
13.1.2 Key Persons
13.1.3 Product Portfolio
13.1.4 Recent Development
13.1.5 Revenue Analysis
13.2 Biocon Limited
13.2.1 Overview
13.2.2 Key Persons
13.2.3 Product Portfolio
13.2.4 Recent Development
13.2.5 Revenue Analysis
13.3 Eli Lilly and Company
13.3.1 Overview
13.3.2 Key Persons
13.3.3 Product Portfolio
13.3.4 Recent Development
13.3.5 Revenue Analysis
13.4 Gan & Lee Pharmaceuticals Co. Ltd.
13.4.1 Overview
13.4.2 Key Persons
13.4.3 Product Portfolio
13.4.4 Recent Development
13.4.5 Revenue Analysis
13.5 Geropharm
13.5.1 Overview
13.5.2 Key Persons
13.5.3 Product Portfolio
13.5.4 Recent Development
13.5.5 Revenue Analysis
13.6 MannKind Corporation
13.6.1 Overview
13.6.2 Key Persons
13.6.3 Product Portfolio
13.6.4 Recent Development
13.6.5 Revenue Analysis
13.7 Merck & Co. Inc.
13.7.1 Overview
13.7.2 Key Persons
13.7.3 Product Portfolio
13.7.4 Recent Development
13.7.5 Revenue Analysis
13.8 Novo Nordisk A/S
13.8.1 Overview
13.8.2 Key Persons
13.8.3 Product Portfolio
13.8.4 Recent Development
13.8.5 Revenue Analysis
13.9 Sanofi S.A.
13.9.1 Overview
13.9.2 Key Persons
13.9.3 Product Portfolio
13.9.4 Recent Development
13.9.5 Revenue Analysis
13.10 Wockhardt Ltd.
13.10.1 Overview
13.10.2 Key Persons
13.10.3 Product Portfolio
13.10.4 Recent Development
13.10.5 Revenue Analysis
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com